I'm simple and do not have a scientific background to
I'm simple and do not have a scientific background to understand all that Gerald said in his blog. I remember when he has talked about other AD diagnostic tests such as Amivid that is much more invasive (they stick something in your spin), more expensive ($3,000 dollars?), and less accurate (70 to 83% range for sensitivity and specificity) When I became familiar with the LymPro blood test I remember numbers like 91% and 92% specificity and sensitivity, and we only drew blood, we didn't put something in people's spins.
That is the simple level I understand things at. When it was presented to me in that light, it was a no brainer for me to come to the conclusion that LymPro, once commercialized, would immediately become the "Industry Standard" (over 2 or 3 years time)
I know BD did a "Validation Study" on LymPro in 2013, but I'm not sure what those results were compared to the "Pilot Test" they said they would do Q1 2014, or the larger 160 patient "Analytical Performance" Test supposed to be completed in Q2 of 2014. Those are the names of the tests that stuck in my mind which Gerald spoke to us about in the final months of 2013. Does anyone else remember them that way? Because based on what Gerald said in his blog....I can't make the connections. Even though all those tests should be completed right now, I'm not sure how to identify the results of each and compare it to the original 91% and 92% sensitivity & specificity numbers I mentioned up above. It all seems to be morphed together....blurred....so that after reading Gerald's blog....I'm still needing someone to communicate to me in a way I understand.
And really, I'm not an idiot. I'm smart. Now I'm sounding like Freddo. Could someone connect the dots for me in plain English? I still don't know if the results to be reported on July 31st will be the specificity & sensitivity numbers in the mid 90s or whether that is a goal that we'll work for once we're in our CLIA partner's lab sometime in October or November. If that is the case, this stock is going nowhere on July 31st!!
Can someone clear this up for me?
Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Breaking Down the AI Music Race In the wild world of music production, AI's making waves. Here's the thing though—it's all about how fast and how much it can churn out. Now, won't lie to you, that's impressive, but not the full picture. Pat Villaceran, the brain behind CITY JAM, is adamant that the real gold isn't just speed. It's the unique sound each artist brings to...
Continue Reading
Defining Energy Horizons in Riyadh Mark those calendars, because as the global energy crowd descends on Riyadh from October 11 to 15, 2026, KAPSARC steps into the spotlight. As the National Partner at the 25th World Petroleum Congress (WPC), they're not just warming the bench—they're playing every position, shaking up the field of energy. Paving the Pathways with...
Continue Reading
CenterPoint’s Commitment Amidst Crisis Now, when a hurricane slams into the coast, it’s go time for everyone in the game. CenterPoint Energy, never one to sit on the sidelines, is showing up with a hefty squad to help fix the mess left by Hurricane Isaias. A robust 355-strong team is heading out to assist with power restoration down there in Florida. This isn’t just...
Continue Reading
A Boom in Self-Directed Investing Times are changing, folks. More people than ever are taking finance into their own hands, wielding smartphones like fiscal swords in the name of self-directed investment. No middlemen, no fancy office, just straight-up trading from wherever you might be perched. Four major platforms now boast over 41 million funded accounts combined, each...
Continue Reading
A Fresh Look at ONLYOFFICE 10.0's Game-Changing Update Outta the gates swinging, ONLYOFFICE dropped their latest 10.0 update. This one ain't just your average software facelift—it's packing some serious heat with AI enhancements, brand spanking new modular apps, and beefed-up security features that'll make anyone dealing with sensitive data breathe a little easier. AI...
Continue Reading
The High-Stakes Race for Data Center Power These days, if you're not talking about data centers, you're probably a step behind the curve. AI's explosive growth is pushing data center developments across North America like never before. Larger campuses, hefty power densities—it's all happening at a pace that's got everyone scrambling. For folks like NOARK Electric, this...
Continue Reading
Tutu Robots Usher in a New Technological Era for Sands China Alright, let's dive into some tech that feels out of a sci-fi movie and see what Sands China and Amap have cooked up as they introduce the Tutu robot dogs to Sands Resorts Macau. These aren't your run-of-the-mill gadgets—they're futuristic tour guides ready to rewire visitor experiences. The delivery ceremony...
Continue Reading
FDA Clearance: A Major Step for RingConn In a space where every tiny gadget-maker is desperately clawing for a regulatory nod, RingConn—a venture born from Shenzhen Ninenovo Technology Limited—has snagged an FDA 510(k) clearance (Clearance No. K260490) for their wearable Smart Ring that measures blood oxygen levels non-invasively. October 10, 2026, marked the day when...
Continue Reading
Arrvel's Thermal Printing Push: An Overview No one would have pegged tiny thermal label printers as game-changers, but here we are. Arrvel's new lineup of thermal printers is shaking up the world for anyone who's ever had to slap on a shipping label or get inventory organized. They're targeting e-commerce folks and small businesses, which sounds like the right move as...
Continue Reading
Now here's something that'll tickle your ophthalmologist's fancy—Haag-Streit USA has rolled out the Octopus 910, a slick piece of kit set to shake up visual field testing for glaucoma management. This time, they're getting in front of the competition, unveiling it at the Association for Research in Vision and Ophthalmology's 2026 shindig in New Orleans. With this new...
Continue Reading
Top 5 Most Recently Viewed Articles
Derek Chang Takes the Helm at Liberty Media Liberty Media is excited to announce the appointment of Derek Chang as its President and Chief Executive Officer. This transition is set to take place, indicating a new chapter for the company. With a wealth of experience and a comprehensive background in the media and entertainment sectors, Chang brings a unique perspective to...
Continue Reading
Overview of Financial Performance Steelcase Inc. recently reported strong financial results for the second quarter of fiscal 2025. This quarter demonstrated significant improvements and growth compared to the same time last year. Key Financial Metrics During the second quarter, Steelcase revealed a revenue of $855.8 million, which is a slight rise from last year’s...
Continue Reading
Innovative Class Scheduling Feature for Small Businesses Bookedin, an innovative platform, has recently introduced its latest feature aimed at empowering small businesses with efficient class scheduling capabilities. This new feature is tailored for fitness studios, yoga centers, tutors, coaches, and anyone involved in organizing classes or workshops. The primary focus is...
Continue Reading
Ares Management's Short Interest Overview Ares Management (ARES) has witnessed a notable increase in its short percent of float, which has risen by 3.4% since the last reporting period. Currently, the company has reported 3.90 million shares sold short, reflecting 2.13% of the total shares available for trading. At the current trading volume, it would take about 3.44 days...
Continue Reading
ONWARD Medical Receives Buy Rating from BNP Paribas Group ONWARD Medical N.V. is a trailblazing neurotechnology company focused on developing innovative therapies aimed at restoring movement and independence for individuals affected by spinal cord injuries (SCI) and related mobility challenges. Recently, the company received significant attention from BNP Paribas’...
Continue Reading